Literature DB >> 27308097

Diagnostic Value of Cell-free Circulating MicroRNAs for Obesity and Type 2 Diabetes: A Meta-analysis.

Audrey Villard1, Lucien Marchand2, Charles Thivolet3, Sophie Rome1.   

Abstract

Type 2 diabetes mellitus (T2DM) is the most common metabolic disorder worldwide. Because of population aging and increasing trends toward obesity and sedentary lifestyles, the number of affected individuals is increasing at worrisome rates. While both environmental and genetic factors are known to contribute to the development of T2DM, continuous research is needed to identify specific biomarkers that could aid both in prevention of the disease and development of newer therapeutic options. Circulating miRNAs are considered as potential biomarkers because they are stable and resistant to degradation by blood RNAses and are modified under different pathophysiological conditions. In this study we carried out a systematic electronic search on PubMed to retrieve all articles that have investigated circulating miRNAs for diagnosing obesity andT2DM in human. We also included lifestyle intervention studies known to be highly effective in delaying onset of diabetes, and studies analyzing the effect of bariatric surgery and anti-diabetic treatment. A total of 26 studies were enrolled in the global meta-analysis. Candidate miRNAs were defined as those reported in at least 2 studies with same direction of differential expression. Ten miRNAs altered in blood of patients suffering fromT2DM were identified (increased: miR-320a, miR-142-3p, miR-222, miR-29a, miR-27a, miR-375; decreased: miR-197, miR-20b, miR-17, miR-652) and 7 miRNAs in blood of obese subjects were identified (increased: miR-142-3p, miR-140-5p, miR-222; decreased:miR-21-5p, miR-221-3p, miR-125-5p, mir-103-5p). Both obese and T2DM patients had elevated concentrations of miR-142-3p and miR-222. MiRNAs target genes were predicted and their cellular functions are discussed in relation with the pathologies. Although a significant number of studies were taken into account in this review, we found a strong discrepancy between miRNA detection and quantification indicating that many of pre-analytical variables have yet to be normalized. Pre-analytical and analytical challenges are also discussed.

Entities:  

Keywords:  Circulating miRNAs; Meta-analysis; Obesity; Type 2 diabetes

Year:  2015        PMID: 27308097      PMCID: PMC4905583          DOI: 10.4172/2155-9929.1000251

Source DB:  PubMed          Journal:  J Mol Biomark Diagn


  96 in total

1.  MicroRNA expression in relation to different dietary habits: a comparison in stool and plasma samples.

Authors:  Sonia Tarallo; Barbara Pardini; Giuseppe Mancuso; Fabio Rosa; Cornelia Di Gaetano; Floriano Rosina; Paolo Vineis; Alessio Naccarati
Journal:  Mutagenesis       Date:  2014-09       Impact factor: 3.000

2.  Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA.

Authors:  Jianjian Gao; Qingyun Zhang; Jianjun Xu; Lijuan Guo; Xuefeng Li
Journal:  Chin J Cancer Res       Date:  2013-12       Impact factor: 5.087

Review 3.  MicroRNAs and type 2 diabetes/obesity.

Authors:  Mustafa Abdo Saif Dehwah; Aimin Xu; Qingyang Huang
Journal:  J Genet Genomics       Date:  2011-12-29       Impact factor: 4.275

4.  microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3.

Authors:  Dongqi Yu; Huaijun Zhou; Qingying Xun; Xiaofeng Xu; Jingxian Ling; Yali Hu
Journal:  Oncol Lett       Date:  2012-03-08       Impact factor: 2.967

5.  Circulating miRNA profiles in patients with metabolic syndrome.

Authors:  Dwi Setyowati Karolina; Subramaniam Tavintharan; Arunmozhiarasi Armugam; Sugunavathi Sepramaniam; Sharon Li Ting Pek; Michael T K Wong; Su Chi Lim; Chee Fang Sum; Kandiah Jeyaseelan
Journal:  J Clin Endocrinol Metab       Date:  2012-10-02       Impact factor: 5.958

6.  Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization.

Authors:  Francisco J Ortega; Josep M Mercader; José María Moreno-Navarrete; Oscar Rovira; Ester Guerra; Eduardo Esteve; Gemma Xifra; Cristina Martínez; Wifredo Ricart; Jennifer Rieusset; Sophie Rome; Monika Karczewska-Kupczewska; Marek Straczkowski; José Manuel Fernández-Real
Journal:  Diabetes Care       Date:  2014-01-29       Impact factor: 19.112

7.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

8.  MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus.

Authors:  Dwi Setyowati Karolina; Arunmozhiarasi Armugam; Subramaniam Tavintharan; Michael T K Wong; Su Chi Lim; Chee Fang Sum; Kandiah Jeyaseelan
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

9.  Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers.

Authors:  Verena Köberle; Thomas Pleli; Christian Schmithals; Eduardo Augusto Alonso; Jörg Haupenthal; Halvard Bönig; Jan Peveling-Oberhag; Ricardo M Biondi; Stefan Zeuzem; Bernd Kronenberger; Oliver Waidmann; Albrecht Piiper
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

10.  Assessing an improved protocol for plasma microRNA extraction.

Authors:  Inés Moret; Dolors Sánchez-Izquierdo; Marisa Iborra; Luis Tortosa; Ana Navarro-Puche; Pilar Nos; José Cervera; Belén Beltrán
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

View more
  37 in total

Review 1.  Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease.

Authors:  Marcelo A Mori; Raissa G Ludwig; Ruben Garcia-Martin; Bruna B Brandão; C Ronald Kahn
Journal:  Cell Metab       Date:  2019-08-22       Impact factor: 27.287

Review 2.  MicroRNAs as biomarkers for clinical studies.

Authors:  Igor P Pogribny
Journal:  Exp Biol Med (Maywood)       Date:  2017-09-15

3.  Circulating early- and mid-pregnancy microRNAs and risk of gestational diabetes.

Authors:  Pandora L Wander; Edward J Boyko; Karin Hevner; Viraj J Parikh; Mahlet G Tadesse; Tanya K Sorensen; Michelle A Williams; Daniel A Enquobahrie
Journal:  Diabetes Res Clin Pract       Date:  2017-07-25       Impact factor: 5.602

Review 4.  Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome.

Authors:  C Ronald Kahn; Guoxiao Wang; Kevin Y Lee
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

Review 5.  Mitochondrial miRNAs in diabetes: just the tip of the iceberg.

Authors:  Rohini Baradan; John M Hollander; Samarjit Das
Journal:  Can J Physiol Pharmacol       Date:  2017-05-03       Impact factor: 2.273

6.  Hypothalamic miR-1983 Targets Insulin Receptor β and the Insulin-mediated miR-1983 Increase Is Blocked by Metformin.

Authors:  Jennifer A Chalmers; Prasad S Dalvi; Neruja Loganathan; Emma K McIlwraith; Leigh Wellhauser; Anaies Nazarians-Armavil; Judith A Eversley; Haneesha Mohan; Priska Stahel; Satya Dash; Michael B Wheeler; Denise D Belsham
Journal:  Endocrinology       Date:  2022-01-01       Impact factor: 4.736

Review 7.  Exosomes as mediators of intercellular crosstalk in metabolism.

Authors:  Roi Isaac; Felipe Castellani Gomes Reis; Wei Ying; Jerrold M Olefsky
Journal:  Cell Metab       Date:  2021-09-07       Impact factor: 31.373

Review 8.  Insight into the Role of the PI3K/Akt Pathway in Ischemic Injury and Post-Infarct Left Ventricular Remodeling in Normal and Diabetic Heart.

Authors:  Bartosz Walkowski; Marcin Kleibert; Miłosz Majka; Małgorzata Wojciechowska
Journal:  Cells       Date:  2022-05-05       Impact factor: 7.666

9.  Distribution of microRNA biomarker candidates in solid tissues and body fluids.

Authors:  Tobias Fehlmann; Nicole Ludwig; Christina Backes; Eckart Meese; Andreas Keller
Journal:  RNA Biol       Date:  2016-09-29       Impact factor: 4.652

10.  miR-140-5p Aggravates Insulin Resistance via Directly Targeting GYS1 and PPP1CC in Insulin-Resistant HepG2 Cells.

Authors:  Xuemei Li; Shujun Zhao; Yan Ye; Baoli Wang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-06-04       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.